2,6-difluoro-4-(9-(4-hydroxyphenyl)-9H-purin-2-ylamino)phenol

ID: ALA4865383

PubChem CID: 164621370

Max Phase: Preclinical

Molecular Formula: C17H11F2N5O2

Molecular Weight: 355.30

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  Oc1ccc(-n2cnc3cnc(Nc4cc(F)c(O)c(F)c4)nc32)cc1

Standard InChI:  InChI=1S/C17H11F2N5O2/c18-12-5-9(6-13(19)15(12)26)22-17-20-7-14-16(23-17)24(8-21-14)10-1-3-11(25)4-2-10/h1-8,25-26H,(H,20,22,23)

Standard InChI Key:  REIKFAGJACMEBJ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
   11.7629  -21.0507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7617  -21.8776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4761  -22.2903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1922  -21.8772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1893  -21.0471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4743  -20.6382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4719  -19.8137    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.0487  -20.6387    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.0473  -22.2894    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   13.9069  -22.2884    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.6203  -21.8749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.3317  -22.2866    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.3240  -20.6375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.6141  -21.0525    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.0406  -21.0422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0474  -21.8699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8452  -22.1401    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.3179  -21.4455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8257  -20.7798    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.1069  -22.9199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5591  -23.5376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8205  -24.3188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6294  -24.4834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.1763  -23.8607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9120  -23.0818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8922  -25.2594    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  6  7  1  0
  1  8  1  0
  2  9  1  0
  4 10  1  0
 10 11  1  0
 11 12  2  0
 12 16  1  0
 15 13  1  0
 13 14  2  0
 14 11  1  0
 15 16  2  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 15  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 20  1  0
 17 20  1  0
 23 26  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4865383

    ---

Associated Targets(Human)

RPS6KA3 Tchem Ribosomal protein S6 kinase alpha 3 (4284 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 355.30Molecular Weight (Monoisotopic): 355.0881AlogP: 3.25#Rotatable Bonds: 3
Polar Surface Area: 96.09Molecular Species: NEUTRALHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 8.28CX Basic pKa: 1.09CX LogP: 3.38CX LogD: 3.33
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.49Np Likeness Score: -1.05

References

1. Casalvieri KA, Matheson CJ, Warfield BM, Backos DS, Reigan P..  (2021)  N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors.,  41  [PMID:34034149] [10.1016/j.bmc.2021.116220]

Source